Twelve-Month Chronic Efficacy and Safety of Diepalrestat in Adult Subjects With Diabetic Peripheral Neuropathy (DPN), A Randomized, Double-Blind, Placebo-Controlled Study

Trial Profile

Twelve-Month Chronic Efficacy and Safety of Diepalrestat in Adult Subjects With Diabetic Peripheral Neuropathy (DPN), A Randomized, Double-Blind, Placebo-Controlled Study

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Epalrestat (Primary)
  • Indications Diabetic neuropathies
  • Focus Therapeutic Use
  • Sponsors NeuroMax
  • Most Recent Events

    • 16 May 2016 According to a BioNevia Pharmaceuticals media release, assuming a positive trial outcome, the company is targeting an End of Phase 2 Meeting with the FDA for the second half of 2017.
    • 16 May 2016 According to a Bionevia Pharmaceuticals media release, status changed from recruiting to active, no longer recruiting.
    • 04 Dec 2015 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top